BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33796405)

  • 1. Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.
    Arends R; Guo X; Baverel PG; González-García I; Xie J; Morsli N; Yovine A; Roskos LK
    Oncoimmunology; 2021 Mar; 10(1):1898104. PubMed ID: 33796405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
    Seiwert TY; Wildsmith S; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Baker V; Evans B; Morsli N; Jill Walker ; Real K; L'Hernault A; Psyrri A
    Cancer Immunol Immunother; 2024 Mar; 73(4):70. PubMed ID: 38430375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Wildsmith S; Li W; Wu S; Stewart R; Morsli N; Raja R; Zhang Q; Ye J; He P; Shetty J; Yovine A; Holoweckyj N; Real K; Walker J; Wrona M; de Los Reyes M; Barker C; Whiteley J; Haddad R; Licitra L; Ferris R; Fayette J; Zandberg DP; Siu LL; Mesía R
    Clin Cancer Res; 2023 Jun; 29(11):2066-2074. PubMed ID: 36806911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
    Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
    Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
    Segal NH; Ou SI; Balmanoukian A; Fury MG; Massarelli E; Brahmer JR; Weiss J; Schöffski P; Antonia SJ; Massard C; Zandberg DP; Khleif SN; Xiao F; Rebelatto MC; Steele KE; Robbins PB; Angra N; Song X; Abdullah S; Butler M
    Eur J Cancer; 2019 Mar; 109():154-161. PubMed ID: 30731276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation.
    Wildsmith S; Ye J; Franks A; Melillo G; Armstrong J; Whiteley J; Schnittker K; Lian F; Roland B; Sabalos C; Ahmadi P; Fayette J; Even C; Mesía R; Siu LL; Zandberg DP; Walker J
    Cancer Res Commun; 2022 Jan; 2(1):39-48. PubMed ID: 36860696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Kim DH; Lim ST; Kim HR; Kang EJ; Ahn HK; Lee YG; Sun S; Kwon JH; Lee SC; Lee HW; Kim MK; Keam B; Park KU; Shin SH; Yun HJ
    Oral Oncol; 2024 Apr; 151():106739. PubMed ID: 38458039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
    Moutafi M; Koliou GA; Papaxoinis G; Economopoulou P; Kotsantis I; Gkotzamanidou M; Anastasiou M; Pectasides D; Kyrodimos E; Delides A; Giotakis E; Papadimitriou NG; Panayiotides IG; Perisanidis C; Fernandez AI; Xirou V; Poulios C; Gagari E; Yaghoobi V; Gavrielatou N; Shafi S; Aung TN; Kougioumtzopoulou A; Kouloulias V; Palialexis K; Gkolfinopoulos S; Strati A; Lianidou E; Fountzilas G; Rimm DL; Foukas PG; Psyrri A
    Cancer Res Commun; 2023 Aug; 3(8):1514-1523. PubMed ID: 37575280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
    Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
    Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
    Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.
    Levy A; Massard C; Soria JC; Deutsch E
    Eur J Cancer; 2016 Nov; 68():156-162. PubMed ID: 27764686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour cell PD-L1 test for head and neck cancers.
    Kulasinghe A; Kenny L; Punyadeera C
    Oral Oncol; 2017 Dec; 75():6-7. PubMed ID: 29224824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
    Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
    Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
    Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L2 based immune signature confers poor prognosis in HNSCC.
    Qiao Y; Liu C; Zhang X; Zhou Q; Li Y; Xu Y; Gao Z; Xu Y; Kong L; Yang A; Mei M; Ren Y; Wang X; Zhou X
    Oncoimmunology; 2021; 10(1):1947569. PubMed ID: 34377590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.